Thus, we propose that the combination of EMT inhibitors with antibodies against glycosylated forms of PD-L1 will improve the therapeutic outcome of PD-1/PD-L1 therapies in patients with breast cancer, specifically with the TN phenotype. This evidence concerns the gene CD274 and breast cancer.